Johnson & Johnson Stock - Analysts weigh prospects after recent pullback

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:09 CET. Details in the imprint.

Johnson & Johnson (US4781601046) remains a heavyweight in global healthcare, yet its stock has recently lagged parts of the sector even as defensive names find support. Analyst data now offer a clearer picture of how the company is valued versus peers.

What recent trading shows

Johnson & Johnson shares most recently closed around $228 on the New York Stock Exchange, implying a market capitalization near $550 billion based on delayed quote data as of 06/18/2026.

The stock declined roughly 2.5% in that session, a move that came as broader healthcare names were mixed and large pharmaceutical peers showed more muted changes.

How the sector comparison looks

Despite the setback, Johnson & Johnson still trades at a trailing price-earnings ratio a little above 26, leaving its valuation broadly in line with other diversified healthcare blue chips.

The company's dividend yield is reported at just above 2.2%, which remains competitive in the pharmaceutical and medical-technology peer group and underpins its role as a defensive income stock.

The product behind the stock

Johnson & Johnson generates revenue across pharmaceuticals, medical devices and consumer health, with key prescription brands in oncology and immunology alongside widely known consumer products such as Tylenol pain relief.

Where the stock trades today

Johnson & Johnson shares (US4781601046) last traded on the New York Stock Exchange at about $228 per share on 06/18/2026, based on delayed pricing in US dollars.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.